Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Kringle Pharma, a Japan-based developer of therapeutics for intractable neurological diseases spun out of Osaka University, has increased its latest round to $15m after raising a ¥740m ($6.5m) extension led by the institution’s Osaka University Venture Capital, with participation from property group Chishima Real Estate and clinical test drugs supplier Miraca’s corporate venturing arm, as well as Yitu Capital, Resona Capital, an unnamed fund co-run by Nanto Bank and Venture Labo Investment, MSF Capital Partners, HT Capital, OKB Capital and…
